Generic Tri-Luma Availability
Tri-Luma is a brand name of fluocinolone/hydroquinone/tretinoin topical, approved by the FDA in the following formulation(s):
TRI-LUMA (fluocinolone acetonide; hydroquinone; tretinoin - cream;topical)
-
Manufacturer: GALDERMA LABS LP
Approval date: January 18, 2002
Strength(s): 0.01%;4%;0.05% [RLD]
Has a generic version of Tri-Luma been approved?
No. There is currently no therapeutically equivalent version of Tri-Luma available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tri-Luma. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical skin care composition
Patent 7,915,243
Issued: March 29, 2011
Inventor(s): Puglia; Nancy & Ramirez; Rosario & Roth; Jerry
Assignee(s): Galderma S.A.
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Patent expiration dates:- March 22, 2026✓
- March 22, 2026
-
Topical skin care composition
Patent 7,939,516
Issued: May 10, 2011
Inventor(s): Puglia; Nancy & Roth; Jerry & Ramirez; Rosario
Assignee(s): Galderma S.A.
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Patent expiration dates:- May 4, 2025✓
- May 4, 2025
-
Topical skin care composition
Patent 8,247,395
Issued: August 21, 2012
Inventor(s): Puglia; Nancy & Roth; Jerry & Ramirez; Rosario
Assignee(s): Galderma S.A.
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Patent expiration dates:- October 22, 2022✓
- October 22, 2022
-
Topical skin care composition
Patent 8,653,053
Issued: February 18, 2014
Assignee(s): Galderma S.A.
A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.Patent expiration dates:- October 25, 2022✓
- October 25, 2022
More about Tri-Luma (fluocinolone / hydroquinone / tretinoin topical)
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
